Literature DB >> 22814720

Integrin-linked kinase (ILK) expression correlates with tumor severity in clear cell renal carcinoma.

Míriam de Fátima Brasil Engelman1, Rogério Mendes Grande, Marcelo Andery Naves, Marcello Fabiano de Franco, Vicente de Paulo Castro Teixeira.   

Abstract

Integrin-linked kinase (ILK) is an unique intracellular serine/threonine kinase and adapter protein. When dysregulated, it has been associated with increased cell proliferation, anchorage-independent cell growth, evasion of apoptosis, angiogenesis, invasion of surrounding tissues, downregulation of E-cadherin expression, nuclear translocation of β-catenin and metastasis, all features of tumoral malignancy. The objective of the present work was to evaluate the expression of ILK in clear cell renal carcinomas (CCRC) as a possible prognostic indicator. ILK immunoexpression was evaluated in a tissue microarray (TMA) with 45 human CCRCs. In addition, the apoptotic and proliferative indices and the immuno-expression of β-catenin and E-cadherin were also evaluated. E-cadherin expression was significantly decreased in tumors with positive ILK expression in relation to those with negative immunoexpression (p = 0.011). ILK immunostaining was significantly increased in high-grade in comparison to low-grade CCRCs (p = 0.0008). ILK expression was also associated with increased proliferative index (p = 0.020), tumor size >7.0 cm (p = 0.018) and with renal vein and capsule invasion (p = 0.003 and p = 0.00). Finally, tumors stage I and II (noninvasive) presented significantly reduced ILK immunoexpression when compared to stage III (locally invasive) (p = 0.0028). ILK immunoexpression in CCRC increases with loss of intercellular adhesion, nuclear grading, increased proliferative index and Robson stage. Altogether, our data suggest a possible role for ILK in the progression of CRCC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22814720     DOI: 10.1007/s12253-012-9554-4

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  44 in total

1.  ILK (beta1-integrin-linked protein kinase): a novel immunohistochemical marker for Ewing's sarcoma and primitive neuroectodermal tumour.

Authors:  D H Chung; J I Lee; M C Kook; J R Kim; S H Kim; E Y Choi; S H Park; H G Song
Journal:  Virchows Arch       Date:  1998-08       Impact factor: 4.064

2.  Integrin-linked kinase is a potential therapeutic target for anaplastic thyroid cancer.

Authors:  Maher N Younes; Seungwon Kim; Orhan G Yigitbasi; Mahitosh Mandal; Samar A Jasser; Yasemin Dakak Yazici; Bradley A Schiff; Adel El-Naggar; Benjamin N Bekele; Gordon B Mills; Jeffrey N Myers
Journal:  Mol Cancer Ther       Date:  2005-08       Impact factor: 6.261

3.  ILK expression in human basal cell carcinoma correlates with epithelial-mesenchymal transition markers and tumour invasion.

Authors:  Sofia Papanikolaou; Vasiliki Bravou; Konstantinos Gyftopoulos; Dimitrios Nakas; Maria Repanti; Helen Papadaki
Journal:  Histopathology       Date:  2010-05       Impact factor: 5.087

4.  The importance of integrin-linked kinase in the regulation of bladder cancer invasion.

Authors:  Yoshiyuki Matsui; Kiran Assi; Osamu Ogawa; Peter A Raven; Shoukat Dedhar; Martin E Gleave; Baljinder Salh; Alan I So
Journal:  Int J Cancer       Date:  2011-05-28       Impact factor: 7.396

Review 5.  Integrin-linked kinase: a cancer therapeutic target unique among its ILK.

Authors:  Gregory Hannigan; Armelle A Troussard; Shoukat Dedhar
Journal:  Nat Rev Cancer       Date:  2005-01       Impact factor: 60.716

6.  Quantitative evaluation of apoptosis and proliferation in renal cell carcinoma. Correlation to tumor subtype, cytological grade according to thoenes-classification and the occurrence of metastasis.

Authors:  W Hindermann; A Berndt; H Wunderlich; D Katenkamp; H Kosmehl
Journal:  Pathol Res Pract       Date:  1997       Impact factor: 3.250

Review 7.  beta-Catenin signaling: therapeutic strategies in oncology.

Authors:  Han Li; Rifat Pamukcu; W Joseph Thompson
Journal:  Cancer Biol Ther       Date:  2002 Nov-Dec       Impact factor: 4.742

8.  Integrin-linked kinase expression increases with ovarian tumour grade and is sustained by peritoneal tumour fluid.

Authors:  Nuzhat Ahmed; Clyde Riley; Karen Oliva; Emma Stutt; Greg E Rice; Michael A Quinn
Journal:  J Pathol       Date:  2003-10       Impact factor: 7.996

9.  Tumor expression of integrin-linked kinase (ILK) correlates with the expression of the E-cadherin repressor snail: an immunohistochemical study in ductal pancreatic adenocarcinoma.

Authors:  David F Schaeffer; Kiran Assi; Katie Chan; Andrzej K Buczkowski; Stephen W Chung; Charles H Scudamore; Alan Weiss; Bill Salh; David A Owen
Journal:  Virchows Arch       Date:  2010-01-21       Impact factor: 4.064

10.  Expression of integrin-linked kinase is increased in differentiated cells.

Authors:  Michael Haase; Christine C Gmach; Iris Eke; Stephanie Hehlgans; Gustavo B Baretton; Nils Cordes
Journal:  J Histochem Cytochem       Date:  2008-05-27       Impact factor: 2.479

View more
  3 in total

1.  Integrin-Linked Kinase Deficiency in Collecting Duct Principal Cell Promotes Necroptosis of Principal Cell and Contributes to Kidney Inflammation and Fibrosis.

Authors:  Ming Huang; Shuai Zhu; Huihui Huang; Jinzhao He; Kenji Tsuji; William W Jin; Dongping Xie; Onju Ham; Diane E Capen; Weining Lu; Teodor G Păunescu; Baoxue Yang; Hua A Jenny Lu
Journal:  J Am Soc Nephrol       Date:  2019-10-25       Impact factor: 10.121

2.  Neuroendocrine tumors of the pancreas: a retrospective single-center analysis using the ENETS TNM-classification and immunohistochemical markers for risk stratification.

Authors:  Stefan M Brunner; Florian Weber; Jens M Werner; Ayman Agha; Stefan A Farkas; Hans J Schlitt; Matthias Hornung
Journal:  BMC Surg       Date:  2015-04-25       Impact factor: 2.102

3.  Activated Integrin-Linked Kinase Negatively Regulates Muscle Cell Enhancement Factor 2C in C2C12 Cells.

Authors:  Zhenguo Dong; Wei Pan; Haiqing Wu; Dongjun Liu; Ming Cang
Journal:  Biomed Res Int       Date:  2015-12-16       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.